nodes	percent_of_prediction	percent_of_DWPC	metapath
Pseudoephedrine—IL2—hematologic cancer	0.323	0.748	CbGaD
Pseudoephedrine—TNF—Thalidomide—hematologic cancer	0.149	0.638	CbGbCtD
Pseudoephedrine—TNF—hematologic cancer	0.109	0.252	CbGaD
Pseudoephedrine—CYP2D6—Lomustine—hematologic cancer	0.016	0.0684	CbGbCtD
Pseudoephedrine—CYP2D6—Idarubicin—hematologic cancer	0.0143	0.061	CbGbCtD
Pseudoephedrine—CYP2D6—Hydroxyurea—hematologic cancer	0.0121	0.0519	CbGbCtD
Pseudoephedrine—CYP2D6—Bortezomib—hematologic cancer	0.0105	0.0451	CbGbCtD
Pseudoephedrine—CYP2D6—Imatinib—hematologic cancer	0.00773	0.0331	CbGbCtD
Pseudoephedrine—CYP2D6—Nilotinib—hematologic cancer	0.00702	0.03	CbGbCtD
Pseudoephedrine—CYP2D6—Vinorelbine—hematologic cancer	0.00696	0.0298	CbGbCtD
Pseudoephedrine—CYP2D6—Vinblastine—hematologic cancer	0.00429	0.0184	CbGbCtD
Pseudoephedrine—NFATC1—hematopoietic system—hematologic cancer	0.00425	0.0902	CbGeAlD
Pseudoephedrine—IL2—hematopoietic system—hematologic cancer	0.00389	0.0825	CbGeAlD
Pseudoephedrine—CYP2D6—Dexamethasone—hematologic cancer	0.00318	0.0136	CbGbCtD
Pseudoephedrine—NFATC1—blood—hematologic cancer	0.00281	0.0598	CbGeAlD
Pseudoephedrine—NFATC1—bone marrow—hematologic cancer	0.00272	0.0578	CbGeAlD
Pseudoephedrine—TNF—blood—hematologic cancer	0.00269	0.057	CbGeAlD
Pseudoephedrine—CYP2D6—Doxorubicin—hematologic cancer	0.00264	0.0113	CbGbCtD
Pseudoephedrine—IL2—blood—hematologic cancer	0.00257	0.0547	CbGeAlD
Pseudoephedrine—IL2—bone marrow—hematologic cancer	0.00249	0.0529	CbGeAlD
Pseudoephedrine—NFATC1—lung—hematologic cancer	0.00247	0.0524	CbGeAlD
Pseudoephedrine—NFATC1—testis—hematologic cancer	0.00233	0.0494	CbGeAlD
Pseudoephedrine—IL2—lung—hematologic cancer	0.00226	0.0479	CbGeAlD
Pseudoephedrine—NFATC1—lymph node—hematologic cancer	0.00169	0.0358	CbGeAlD
Pseudoephedrine—TNF—lymph node—hematologic cancer	0.00161	0.0342	CbGeAlD
Pseudoephedrine—IL2—lymph node—hematologic cancer	0.00154	0.0328	CbGeAlD
Pseudoephedrine—SLC6A3—hematopoietic system—hematologic cancer	0.00103	0.0218	CbGeAlD
Pseudoephedrine—SLC6A4—hematopoietic system—hematologic cancer	0.000941	0.02	CbGeAlD
Pseudoephedrine—ADRA1A—hematopoietic system—hematologic cancer	0.00077	0.0163	CbGeAlD
Pseudoephedrine—MAOA—hematopoietic system—hematologic cancer	0.000763	0.0162	CbGeAlD
Pseudoephedrine—SLC6A2—gonad—hematologic cancer	0.00063	0.0134	CbGeAlD
Pseudoephedrine—SLC6A4—blood—hematologic cancer	0.000623	0.0132	CbGeAlD
Pseudoephedrine—SLC6A3—lung—hematologic cancer	0.000596	0.0127	CbGeAlD
Pseudoephedrine—ADRA2A—hematopoietic system—hematologic cancer	0.000586	0.0124	CbGeAlD
Pseudoephedrine—ADRB1—lung—hematologic cancer	0.000566	0.012	CbGeAlD
Pseudoephedrine—SLC6A3—testis—hematologic cancer	0.000563	0.0119	CbGeAlD
Pseudoephedrine—SLC6A4—lung—hematologic cancer	0.000546	0.0116	CbGeAlD
Pseudoephedrine—ADRA1A—blood—hematologic cancer	0.00051	0.0108	CbGeAlD
Pseudoephedrine—MAOA—blood—hematologic cancer	0.000506	0.0107	CbGeAlD
Pseudoephedrine—SLC6A2—lung—hematologic cancer	0.000481	0.0102	CbGeAlD
Pseudoephedrine—SLC6A2—testis—hematologic cancer	0.000454	0.00964	CbGeAlD
Pseudoephedrine—CYP2D6—hematopoietic system—hematologic cancer	0.000454	0.00963	CbGeAlD
Pseudoephedrine—ADRA2A—gonad—hematologic cancer	0.000445	0.00945	CbGeAlD
Pseudoephedrine—MAOA—lung—hematologic cancer	0.000443	0.00941	CbGeAlD
Pseudoephedrine—MAOA—testis—hematologic cancer	0.000418	0.00888	CbGeAlD
Pseudoephedrine—ADRA2A—blood—hematologic cancer	0.000388	0.00824	CbGeAlD
Pseudoephedrine—ADRA2A—lung—hematologic cancer	0.00034	0.00722	CbGeAlD
Pseudoephedrine—SLC6A2—lymph node—hematologic cancer	0.000329	0.00699	CbGeAlD
Pseudoephedrine—ADRA2A—testis—hematologic cancer	0.000321	0.00681	CbGeAlD
Pseudoephedrine—MAOA—lymph node—hematologic cancer	0.000303	0.00644	CbGeAlD
Pseudoephedrine—CYP2D6—blood—hematologic cancer	0.0003	0.00638	CbGeAlD
Pseudoephedrine—CYP2D6—testis—hematologic cancer	0.000249	0.00528	CbGeAlD
Pseudoephedrine—ADRA2A—lymph node—hematologic cancer	0.000233	0.00494	CbGeAlD
Pseudoephedrine—Dermatitis—Bleomycin—hematologic cancer	6.67e-05	0.00054	CcSEcCtD
Pseudoephedrine—Asthenia—Carmustine—hematologic cancer	6.63e-05	0.000537	CcSEcCtD
Pseudoephedrine—Vomiting—Vinorelbine—hematologic cancer	6.63e-05	0.000536	CcSEcCtD
Pseudoephedrine—Body temperature increased—Gemcitabine—hematologic cancer	6.62e-05	0.000536	CcSEcCtD
Pseudoephedrine—Dysuria—Epirubicin—hematologic cancer	6.59e-05	0.000533	CcSEcCtD
Pseudoephedrine—Dizziness—Thiotepa—hematologic cancer	6.58e-05	0.000533	CcSEcCtD
Pseudoephedrine—Asthenia—Alitretinoin—hematologic cancer	6.57e-05	0.000532	CcSEcCtD
Pseudoephedrine—Rash—Vinorelbine—hematologic cancer	6.57e-05	0.000532	CcSEcCtD
Pseudoephedrine—Dermatitis—Vinorelbine—hematologic cancer	6.56e-05	0.000531	CcSEcCtD
Pseudoephedrine—Headache—Vinorelbine—hematologic cancer	6.53e-05	0.000528	CcSEcCtD
Pseudoephedrine—Asthenia—Ifosfamide—hematologic cancer	6.49e-05	0.000526	CcSEcCtD
Pseudoephedrine—Vertigo—Betamethasone—hematologic cancer	6.48e-05	0.000524	CcSEcCtD
Pseudoephedrine—Vertigo—Dexamethasone—hematologic cancer	6.48e-05	0.000524	CcSEcCtD
Pseudoephedrine—Arrhythmia—Prednisone—hematologic cancer	6.44e-05	0.000521	CcSEcCtD
Pseudoephedrine—Sweating—Methotrexate—hematologic cancer	6.44e-05	0.000521	CcSEcCtD
Pseudoephedrine—Feeling abnormal—Cisplatin—hematologic cancer	6.43e-05	0.00052	CcSEcCtD
Pseudoephedrine—Insomnia—Prednisolone—hematologic cancer	6.38e-05	0.000516	CcSEcCtD
Pseudoephedrine—Dyspnoea—Etoposide—hematologic cancer	6.37e-05	0.000516	CcSEcCtD
Pseudoephedrine—Dizziness—Thalidomide—hematologic cancer	6.37e-05	0.000515	CcSEcCtD
Pseudoephedrine—Angina pectoris—Doxorubicin—hematologic cancer	6.35e-05	0.000514	CcSEcCtD
Pseudoephedrine—Nausea—Bortezomib—hematologic cancer	6.34e-05	0.000513	CcSEcCtD
Pseudoephedrine—Asthenia—Vincristine—hematologic cancer	6.33e-05	0.000512	CcSEcCtD
Pseudoephedrine—Tachycardia—Triamcinolone—hematologic cancer	6.33e-05	0.000512	CcSEcCtD
Pseudoephedrine—Vomiting—Thiotepa—hematologic cancer	6.33e-05	0.000512	CcSEcCtD
Pseudoephedrine—Nausea—Bleomycin—hematologic cancer	6.29e-05	0.000509	CcSEcCtD
Pseudoephedrine—Rash—Thiotepa—hematologic cancer	6.27e-05	0.000508	CcSEcCtD
Pseudoephedrine—Dermatitis—Thiotepa—hematologic cancer	6.27e-05	0.000507	CcSEcCtD
Pseudoephedrine—Hyperhidrosis—Triamcinolone—hematologic cancer	6.27e-05	0.000507	CcSEcCtD
Pseudoephedrine—Headache—Thiotepa—hematologic cancer	6.23e-05	0.000505	CcSEcCtD
Pseudoephedrine—Hypertension—Dexamethasone—hematologic cancer	6.22e-05	0.000504	CcSEcCtD
Pseudoephedrine—Hypertension—Betamethasone—hematologic cancer	6.22e-05	0.000504	CcSEcCtD
Pseudoephedrine—Decreased appetite—Etoposide—hematologic cancer	6.21e-05	0.000503	CcSEcCtD
Pseudoephedrine—Nausea—Vinorelbine—hematologic cancer	6.19e-05	0.000501	CcSEcCtD
Pseudoephedrine—Body temperature increased—Cisplatin—hematologic cancer	6.17e-05	0.000499	CcSEcCtD
Pseudoephedrine—Asthenia—Mitoxantrone—hematologic cancer	6.17e-05	0.000499	CcSEcCtD
Pseudoephedrine—Asthenia—Irinotecan—hematologic cancer	6.17e-05	0.000499	CcSEcCtD
Pseudoephedrine—Vomiting—Thalidomide—hematologic cancer	6.12e-05	0.000495	CcSEcCtD
Pseudoephedrine—Anxiety—Betamethasone—hematologic cancer	6.12e-05	0.000495	CcSEcCtD
Pseudoephedrine—Anxiety—Dexamethasone—hematologic cancer	6.12e-05	0.000495	CcSEcCtD
Pseudoephedrine—Dizziness—Carmustine—hematologic cancer	6.11e-05	0.000495	CcSEcCtD
Pseudoephedrine—Pain—Etoposide—hematologic cancer	6.11e-05	0.000495	CcSEcCtD
Pseudoephedrine—Dysuria—Doxorubicin—hematologic cancer	6.1e-05	0.000493	CcSEcCtD
Pseudoephedrine—Rash—Thalidomide—hematologic cancer	6.07e-05	0.000491	CcSEcCtD
Pseudoephedrine—Dermatitis—Thalidomide—hematologic cancer	6.06e-05	0.000491	CcSEcCtD
Pseudoephedrine—Dizziness—Alitretinoin—hematologic cancer	6.06e-05	0.00049	CcSEcCtD
Pseudoephedrine—Headache—Thalidomide—hematologic cancer	6.03e-05	0.000488	CcSEcCtD
Pseudoephedrine—Pain—Prednisolone—hematologic cancer	6.03e-05	0.000488	CcSEcCtD
Pseudoephedrine—Sweating—Epirubicin—hematologic cancer	6.02e-05	0.000487	CcSEcCtD
Pseudoephedrine—Asthenia—Gemcitabine—hematologic cancer	6.01e-05	0.000486	CcSEcCtD
Pseudoephedrine—Dizziness—Ifosfamide—hematologic cancer	5.99e-05	0.000484	CcSEcCtD
Pseudoephedrine—Nausea—Thiotepa—hematologic cancer	5.91e-05	0.000478	CcSEcCtD
Pseudoephedrine—Feeling abnormal—Etoposide—hematologic cancer	5.89e-05	0.000477	CcSEcCtD
Pseudoephedrine—Vomiting—Carmustine—hematologic cancer	5.88e-05	0.000476	CcSEcCtD
Pseudoephedrine—Insomnia—Triamcinolone—hematologic cancer	5.86e-05	0.000475	CcSEcCtD
Pseudoephedrine—Dizziness—Vincristine—hematologic cancer	5.84e-05	0.000472	CcSEcCtD
Pseudoephedrine—Rash—Carmustine—hematologic cancer	5.83e-05	0.000472	CcSEcCtD
Pseudoephedrine—Dermatitis—Carmustine—hematologic cancer	5.82e-05	0.000471	CcSEcCtD
Pseudoephedrine—Vomiting—Alitretinoin—hematologic cancer	5.82e-05	0.000471	CcSEcCtD
Pseudoephedrine—Feeling abnormal—Prednisolone—hematologic cancer	5.81e-05	0.00047	CcSEcCtD
Pseudoephedrine—Headache—Carmustine—hematologic cancer	5.79e-05	0.000469	CcSEcCtD
Pseudoephedrine—Dyspnoea—Triamcinolone—hematologic cancer	5.78e-05	0.000468	CcSEcCtD
Pseudoephedrine—Rash—Alitretinoin—hematologic cancer	5.77e-05	0.000467	CcSEcCtD
Pseudoephedrine—Agitation—Prednisone—hematologic cancer	5.77e-05	0.000467	CcSEcCtD
Pseudoephedrine—Dermatitis—Alitretinoin—hematologic cancer	5.77e-05	0.000467	CcSEcCtD
Pseudoephedrine—Vomiting—Ifosfamide—hematologic cancer	5.75e-05	0.000466	CcSEcCtD
Pseudoephedrine—Tachycardia—Betamethasone—hematologic cancer	5.74e-05	0.000465	CcSEcCtD
Pseudoephedrine—Tachycardia—Dexamethasone—hematologic cancer	5.74e-05	0.000465	CcSEcCtD
Pseudoephedrine—Bradycardia—Epirubicin—hematologic cancer	5.74e-05	0.000465	CcSEcCtD
Pseudoephedrine—Headache—Alitretinoin—hematologic cancer	5.74e-05	0.000464	CcSEcCtD
Pseudoephedrine—Nausea—Thalidomide—hematologic cancer	5.72e-05	0.000463	CcSEcCtD
Pseudoephedrine—Dyspepsia—Triamcinolone—hematologic cancer	5.71e-05	0.000462	CcSEcCtD
Pseudoephedrine—Rash—Ifosfamide—hematologic cancer	5.71e-05	0.000462	CcSEcCtD
Pseudoephedrine—Dermatitis—Ifosfamide—hematologic cancer	5.7e-05	0.000461	CcSEcCtD
Pseudoephedrine—Hyperhidrosis—Dexamethasone—hematologic cancer	5.69e-05	0.00046	CcSEcCtD
Pseudoephedrine—Hyperhidrosis—Betamethasone—hematologic cancer	5.69e-05	0.00046	CcSEcCtD
Pseudoephedrine—Dizziness—Irinotecan—hematologic cancer	5.68e-05	0.00046	CcSEcCtD
Pseudoephedrine—Body temperature increased—Etoposide—hematologic cancer	5.65e-05	0.000457	CcSEcCtD
Pseudoephedrine—Vertigo—Prednisone—hematologic cancer	5.64e-05	0.000456	CcSEcCtD
Pseudoephedrine—Vomiting—Vincristine—hematologic cancer	5.61e-05	0.000454	CcSEcCtD
Pseudoephedrine—Anorexia—Betamethasone—hematologic cancer	5.61e-05	0.000454	CcSEcCtD
Pseudoephedrine—Anorexia—Dexamethasone—hematologic cancer	5.61e-05	0.000454	CcSEcCtD
Pseudoephedrine—Asthenia—Cisplatin—hematologic cancer	5.6e-05	0.000453	CcSEcCtD
Pseudoephedrine—Sweating—Doxorubicin—hematologic cancer	5.57e-05	0.000451	CcSEcCtD
Pseudoephedrine—Rash—Vincristine—hematologic cancer	5.56e-05	0.00045	CcSEcCtD
Pseudoephedrine—Dermatitis—Vincristine—hematologic cancer	5.56e-05	0.00045	CcSEcCtD
Pseudoephedrine—Pain—Triamcinolone—hematologic cancer	5.54e-05	0.000449	CcSEcCtD
Pseudoephedrine—Headache—Vincristine—hematologic cancer	5.53e-05	0.000447	CcSEcCtD
Pseudoephedrine—Nausea—Carmustine—hematologic cancer	5.49e-05	0.000444	CcSEcCtD
Pseudoephedrine—Vomiting—Irinotecan—hematologic cancer	5.46e-05	0.000442	CcSEcCtD
Pseudoephedrine—Vomiting—Mitoxantrone—hematologic cancer	5.46e-05	0.000442	CcSEcCtD
Pseudoephedrine—Nausea—Alitretinoin—hematologic cancer	5.44e-05	0.00044	CcSEcCtD
Pseudoephedrine—Hypertension—Prednisone—hematologic cancer	5.42e-05	0.000439	CcSEcCtD
Pseudoephedrine—Rash—Mitoxantrone—hematologic cancer	5.42e-05	0.000439	CcSEcCtD
Pseudoephedrine—Rash—Irinotecan—hematologic cancer	5.42e-05	0.000439	CcSEcCtD
Pseudoephedrine—Dermatitis—Irinotecan—hematologic cancer	5.41e-05	0.000438	CcSEcCtD
Pseudoephedrine—Dermatitis—Mitoxantrone—hematologic cancer	5.41e-05	0.000438	CcSEcCtD
Pseudoephedrine—Headache—Mitoxantrone—hematologic cancer	5.38e-05	0.000436	CcSEcCtD
Pseudoephedrine—Headache—Irinotecan—hematologic cancer	5.38e-05	0.000436	CcSEcCtD
Pseudoephedrine—Nausea—Ifosfamide—hematologic cancer	5.38e-05	0.000435	CcSEcCtD
Pseudoephedrine—Feeling abnormal—Triamcinolone—hematologic cancer	5.34e-05	0.000432	CcSEcCtD
Pseudoephedrine—Anxiety—Prednisone—hematologic cancer	5.33e-05	0.000431	CcSEcCtD
Pseudoephedrine—Vomiting—Gemcitabine—hematologic cancer	5.32e-05	0.000431	CcSEcCtD
Pseudoephedrine—Insomnia—Betamethasone—hematologic cancer	5.32e-05	0.000431	CcSEcCtD
Pseudoephedrine—Insomnia—Dexamethasone—hematologic cancer	5.32e-05	0.000431	CcSEcCtD
Pseudoephedrine—Bradycardia—Doxorubicin—hematologic cancer	5.31e-05	0.00043	CcSEcCtD
Pseudoephedrine—Rash—Gemcitabine—hematologic cancer	5.28e-05	0.000427	CcSEcCtD
Pseudoephedrine—Dermatitis—Gemcitabine—hematologic cancer	5.27e-05	0.000427	CcSEcCtD
Pseudoephedrine—Headache—Gemcitabine—hematologic cancer	5.24e-05	0.000424	CcSEcCtD
Pseudoephedrine—Nausea—Vincristine—hematologic cancer	5.24e-05	0.000424	CcSEcCtD
Pseudoephedrine—Dyspepsia—Betamethasone—hematologic cancer	5.18e-05	0.000419	CcSEcCtD
Pseudoephedrine—Dyspepsia—Dexamethasone—hematologic cancer	5.18e-05	0.000419	CcSEcCtD
Pseudoephedrine—Asthenia—Etoposide—hematologic cancer	5.13e-05	0.000415	CcSEcCtD
Pseudoephedrine—Body temperature increased—Triamcinolone—hematologic cancer	5.13e-05	0.000415	CcSEcCtD
Pseudoephedrine—Decreased appetite—Betamethasone—hematologic cancer	5.11e-05	0.000414	CcSEcCtD
Pseudoephedrine—Decreased appetite—Dexamethasone—hematologic cancer	5.11e-05	0.000414	CcSEcCtD
Pseudoephedrine—Nausea—Mitoxantrone—hematologic cancer	5.1e-05	0.000413	CcSEcCtD
Pseudoephedrine—Nausea—Irinotecan—hematologic cancer	5.1e-05	0.000413	CcSEcCtD
Pseudoephedrine—Arrhythmia—Epirubicin—hematologic cancer	5.04e-05	0.000408	CcSEcCtD
Pseudoephedrine—Pain—Betamethasone—hematologic cancer	5.03e-05	0.000407	CcSEcCtD
Pseudoephedrine—Pain—Dexamethasone—hematologic cancer	5.03e-05	0.000407	CcSEcCtD
Pseudoephedrine—Tachycardia—Prednisone—hematologic cancer	5e-05	0.000405	CcSEcCtD
Pseudoephedrine—Nausea—Gemcitabine—hematologic cancer	4.97e-05	0.000402	CcSEcCtD
Pseudoephedrine—Vomiting—Cisplatin—hematologic cancer	4.96e-05	0.000402	CcSEcCtD
Pseudoephedrine—Hyperhidrosis—Prednisone—hematologic cancer	4.95e-05	0.000401	CcSEcCtD
Pseudoephedrine—Rash—Cisplatin—hematologic cancer	4.92e-05	0.000398	CcSEcCtD
Pseudoephedrine—Dermatitis—Cisplatin—hematologic cancer	4.92e-05	0.000398	CcSEcCtD
Pseudoephedrine—Anorexia—Prednisone—hematologic cancer	4.88e-05	0.000395	CcSEcCtD
Pseudoephedrine—Feeling abnormal—Betamethasone—hematologic cancer	4.85e-05	0.000392	CcSEcCtD
Pseudoephedrine—Feeling abnormal—Dexamethasone—hematologic cancer	4.85e-05	0.000392	CcSEcCtD
Pseudoephedrine—Tension—Epirubicin—hematologic cancer	4.82e-05	0.00039	CcSEcCtD
Pseudoephedrine—Nervousness—Epirubicin—hematologic cancer	4.77e-05	0.000386	CcSEcCtD
Pseudoephedrine—Dizziness—Etoposide—hematologic cancer	4.73e-05	0.000383	CcSEcCtD
Pseudoephedrine—Muscle spasms—Epirubicin—hematologic cancer	4.72e-05	0.000382	CcSEcCtD
Pseudoephedrine—Vertigo—Methotrexate—hematologic cancer	4.71e-05	0.000381	CcSEcCtD
Pseudoephedrine—Dizziness—Prednisolone—hematologic cancer	4.66e-05	0.000377	CcSEcCtD
Pseudoephedrine—Arrhythmia—Doxorubicin—hematologic cancer	4.66e-05	0.000377	CcSEcCtD
Pseudoephedrine—Asthenia—Triamcinolone—hematologic cancer	4.65e-05	0.000376	CcSEcCtD
Pseudoephedrine—Body temperature increased—Dexamethasone—hematologic cancer	4.65e-05	0.000376	CcSEcCtD
Pseudoephedrine—Body temperature increased—Betamethasone—hematologic cancer	4.65e-05	0.000376	CcSEcCtD
Pseudoephedrine—Nausea—Cisplatin—hematologic cancer	4.63e-05	0.000375	CcSEcCtD
Pseudoephedrine—Insomnia—Prednisone—hematologic cancer	4.63e-05	0.000375	CcSEcCtD
Pseudoephedrine—Vomiting—Etoposide—hematologic cancer	4.55e-05	0.000368	CcSEcCtD
Pseudoephedrine—Agitation—Epirubicin—hematologic cancer	4.51e-05	0.000365	CcSEcCtD
Pseudoephedrine—Dyspepsia—Prednisone—hematologic cancer	4.51e-05	0.000365	CcSEcCtD
Pseudoephedrine—Rash—Etoposide—hematologic cancer	4.51e-05	0.000365	CcSEcCtD
Pseudoephedrine—Dermatitis—Etoposide—hematologic cancer	4.5e-05	0.000364	CcSEcCtD
Pseudoephedrine—Headache—Etoposide—hematologic cancer	4.48e-05	0.000362	CcSEcCtD
Pseudoephedrine—Chest pain—Methotrexate—hematologic cancer	4.47e-05	0.000361	CcSEcCtD
Pseudoephedrine—Tension—Doxorubicin—hematologic cancer	4.46e-05	0.000361	CcSEcCtD
Pseudoephedrine—Decreased appetite—Prednisone—hematologic cancer	4.45e-05	0.00036	CcSEcCtD
Pseudoephedrine—Rash—Prednisolone—hematologic cancer	4.45e-05	0.00036	CcSEcCtD
Pseudoephedrine—Dermatitis—Prednisolone—hematologic cancer	4.44e-05	0.000359	CcSEcCtD
Pseudoephedrine—Headache—Prednisolone—hematologic cancer	4.42e-05	0.000357	CcSEcCtD
Pseudoephedrine—Nervousness—Doxorubicin—hematologic cancer	4.41e-05	0.000357	CcSEcCtD
Pseudoephedrine—Vertigo—Epirubicin—hematologic cancer	4.41e-05	0.000357	CcSEcCtD
Pseudoephedrine—Muscle spasms—Doxorubicin—hematologic cancer	4.37e-05	0.000353	CcSEcCtD
Pseudoephedrine—Palpitations—Epirubicin—hematologic cancer	4.34e-05	0.000351	CcSEcCtD
Pseudoephedrine—Confusional state—Methotrexate—hematologic cancer	4.32e-05	0.000349	CcSEcCtD
Pseudoephedrine—Dizziness—Triamcinolone—hematologic cancer	4.29e-05	0.000347	CcSEcCtD
Pseudoephedrine—Nausea—Etoposide—hematologic cancer	4.25e-05	0.000344	CcSEcCtD
Pseudoephedrine—Hypertension—Epirubicin—hematologic cancer	4.24e-05	0.000343	CcSEcCtD
Pseudoephedrine—Feeling abnormal—Prednisone—hematologic cancer	4.22e-05	0.000342	CcSEcCtD
Pseudoephedrine—Asthenia—Betamethasone—hematologic cancer	4.22e-05	0.000342	CcSEcCtD
Pseudoephedrine—Asthenia—Dexamethasone—hematologic cancer	4.22e-05	0.000342	CcSEcCtD
Pseudoephedrine—Nausea—Prednisolone—hematologic cancer	4.19e-05	0.000339	CcSEcCtD
Pseudoephedrine—Chest pain—Epirubicin—hematologic cancer	4.18e-05	0.000338	CcSEcCtD
Pseudoephedrine—Agitation—Doxorubicin—hematologic cancer	4.17e-05	0.000338	CcSEcCtD
Pseudoephedrine—Anxiety—Epirubicin—hematologic cancer	4.17e-05	0.000337	CcSEcCtD
Pseudoephedrine—Hyperhidrosis—Methotrexate—hematologic cancer	4.14e-05	0.000335	CcSEcCtD
Pseudoephedrine—Vomiting—Triamcinolone—hematologic cancer	4.12e-05	0.000334	CcSEcCtD
Pseudoephedrine—Rash—Triamcinolone—hematologic cancer	4.09e-05	0.000331	CcSEcCtD
Pseudoephedrine—Dermatitis—Triamcinolone—hematologic cancer	4.08e-05	0.000331	CcSEcCtD
Pseudoephedrine—Vertigo—Doxorubicin—hematologic cancer	4.08e-05	0.00033	CcSEcCtD
Pseudoephedrine—Anorexia—Methotrexate—hematologic cancer	4.08e-05	0.00033	CcSEcCtD
Pseudoephedrine—Headache—Triamcinolone—hematologic cancer	4.06e-05	0.000329	CcSEcCtD
Pseudoephedrine—Body temperature increased—Prednisone—hematologic cancer	4.05e-05	0.000328	CcSEcCtD
Pseudoephedrine—Confusional state—Epirubicin—hematologic cancer	4.04e-05	0.000327	CcSEcCtD
Pseudoephedrine—Palpitations—Doxorubicin—hematologic cancer	4.01e-05	0.000325	CcSEcCtD
Pseudoephedrine—Hypertension—Doxorubicin—hematologic cancer	3.92e-05	0.000317	CcSEcCtD
Pseudoephedrine—Tachycardia—Epirubicin—hematologic cancer	3.91e-05	0.000316	CcSEcCtD
Pseudoephedrine—Dizziness—Betamethasone—hematologic cancer	3.89e-05	0.000315	CcSEcCtD
Pseudoephedrine—Dizziness—Dexamethasone—hematologic cancer	3.89e-05	0.000315	CcSEcCtD
Pseudoephedrine—Hyperhidrosis—Epirubicin—hematologic cancer	3.87e-05	0.000313	CcSEcCtD
Pseudoephedrine—Insomnia—Methotrexate—hematologic cancer	3.87e-05	0.000313	CcSEcCtD
Pseudoephedrine—Chest pain—Doxorubicin—hematologic cancer	3.87e-05	0.000313	CcSEcCtD
Pseudoephedrine—Anxiety—Doxorubicin—hematologic cancer	3.85e-05	0.000312	CcSEcCtD
Pseudoephedrine—Nausea—Triamcinolone—hematologic cancer	3.85e-05	0.000312	CcSEcCtD
Pseudoephedrine—Anorexia—Epirubicin—hematologic cancer	3.82e-05	0.000309	CcSEcCtD
Pseudoephedrine—Dyspnoea—Methotrexate—hematologic cancer	3.82e-05	0.000309	CcSEcCtD
Pseudoephedrine—Dyspepsia—Methotrexate—hematologic cancer	3.77e-05	0.000305	CcSEcCtD
Pseudoephedrine—Vomiting—Dexamethasone—hematologic cancer	3.74e-05	0.000303	CcSEcCtD
Pseudoephedrine—Vomiting—Betamethasone—hematologic cancer	3.74e-05	0.000303	CcSEcCtD
Pseudoephedrine—Confusional state—Doxorubicin—hematologic cancer	3.74e-05	0.000303	CcSEcCtD
Pseudoephedrine—Decreased appetite—Methotrexate—hematologic cancer	3.72e-05	0.000301	CcSEcCtD
Pseudoephedrine—Rash—Betamethasone—hematologic cancer	3.71e-05	0.0003	CcSEcCtD
Pseudoephedrine—Rash—Dexamethasone—hematologic cancer	3.71e-05	0.0003	CcSEcCtD
Pseudoephedrine—Dermatitis—Dexamethasone—hematologic cancer	3.71e-05	0.0003	CcSEcCtD
Pseudoephedrine—Dermatitis—Betamethasone—hematologic cancer	3.71e-05	0.0003	CcSEcCtD
Pseudoephedrine—Headache—Dexamethasone—hematologic cancer	3.69e-05	0.000298	CcSEcCtD
Pseudoephedrine—Headache—Betamethasone—hematologic cancer	3.69e-05	0.000298	CcSEcCtD
Pseudoephedrine—Asthenia—Prednisone—hematologic cancer	3.68e-05	0.000297	CcSEcCtD
Pseudoephedrine—Pain—Methotrexate—hematologic cancer	3.66e-05	0.000296	CcSEcCtD
Pseudoephedrine—Insomnia—Epirubicin—hematologic cancer	3.62e-05	0.000293	CcSEcCtD
Pseudoephedrine—Tachycardia—Doxorubicin—hematologic cancer	3.62e-05	0.000293	CcSEcCtD
Pseudoephedrine—Hyperhidrosis—Doxorubicin—hematologic cancer	3.58e-05	0.00029	CcSEcCtD
Pseudoephedrine—Dyspnoea—Epirubicin—hematologic cancer	3.57e-05	0.000289	CcSEcCtD
Pseudoephedrine—Anorexia—Doxorubicin—hematologic cancer	3.53e-05	0.000286	CcSEcCtD
Pseudoephedrine—Feeling abnormal—Methotrexate—hematologic cancer	3.53e-05	0.000286	CcSEcCtD
Pseudoephedrine—Dyspepsia—Epirubicin—hematologic cancer	3.53e-05	0.000285	CcSEcCtD
Pseudoephedrine—Nausea—Dexamethasone—hematologic cancer	3.49e-05	0.000283	CcSEcCtD
Pseudoephedrine—Nausea—Betamethasone—hematologic cancer	3.49e-05	0.000283	CcSEcCtD
Pseudoephedrine—Decreased appetite—Epirubicin—hematologic cancer	3.48e-05	0.000282	CcSEcCtD
Pseudoephedrine—Pain—Epirubicin—hematologic cancer	3.43e-05	0.000277	CcSEcCtD
Pseudoephedrine—Dizziness—Prednisone—hematologic cancer	3.39e-05	0.000274	CcSEcCtD
Pseudoephedrine—Body temperature increased—Methotrexate—hematologic cancer	3.38e-05	0.000274	CcSEcCtD
Pseudoephedrine—Insomnia—Doxorubicin—hematologic cancer	3.35e-05	0.000271	CcSEcCtD
Pseudoephedrine—Dyspnoea—Doxorubicin—hematologic cancer	3.31e-05	0.000268	CcSEcCtD
Pseudoephedrine—Feeling abnormal—Epirubicin—hematologic cancer	3.3e-05	0.000267	CcSEcCtD
Pseudoephedrine—Dyspepsia—Doxorubicin—hematologic cancer	3.26e-05	0.000264	CcSEcCtD
Pseudoephedrine—Vomiting—Prednisone—hematologic cancer	3.26e-05	0.000264	CcSEcCtD
Pseudoephedrine—Rash—Prednisone—hematologic cancer	3.23e-05	0.000261	CcSEcCtD
Pseudoephedrine—Dermatitis—Prednisone—hematologic cancer	3.23e-05	0.000261	CcSEcCtD
Pseudoephedrine—Decreased appetite—Doxorubicin—hematologic cancer	3.22e-05	0.000261	CcSEcCtD
Pseudoephedrine—Headache—Prednisone—hematologic cancer	3.21e-05	0.00026	CcSEcCtD
Pseudoephedrine—Pain—Doxorubicin—hematologic cancer	3.17e-05	0.000257	CcSEcCtD
Pseudoephedrine—Body temperature increased—Epirubicin—hematologic cancer	3.17e-05	0.000256	CcSEcCtD
Pseudoephedrine—Asthenia—Methotrexate—hematologic cancer	3.07e-05	0.000249	CcSEcCtD
Pseudoephedrine—Feeling abnormal—Doxorubicin—hematologic cancer	3.06e-05	0.000247	CcSEcCtD
Pseudoephedrine—Nausea—Prednisone—hematologic cancer	3.04e-05	0.000246	CcSEcCtD
Pseudoephedrine—Body temperature increased—Doxorubicin—hematologic cancer	2.93e-05	0.000237	CcSEcCtD
Pseudoephedrine—Asthenia—Epirubicin—hematologic cancer	2.88e-05	0.000233	CcSEcCtD
Pseudoephedrine—Dizziness—Methotrexate—hematologic cancer	2.83e-05	0.000229	CcSEcCtD
Pseudoephedrine—Vomiting—Methotrexate—hematologic cancer	2.72e-05	0.00022	CcSEcCtD
Pseudoephedrine—Rash—Methotrexate—hematologic cancer	2.7e-05	0.000218	CcSEcCtD
Pseudoephedrine—Dermatitis—Methotrexate—hematologic cancer	2.7e-05	0.000218	CcSEcCtD
Pseudoephedrine—Headache—Methotrexate—hematologic cancer	2.68e-05	0.000217	CcSEcCtD
Pseudoephedrine—Asthenia—Doxorubicin—hematologic cancer	2.66e-05	0.000215	CcSEcCtD
Pseudoephedrine—Dizziness—Epirubicin—hematologic cancer	2.65e-05	0.000214	CcSEcCtD
Pseudoephedrine—Vomiting—Epirubicin—hematologic cancer	2.55e-05	0.000206	CcSEcCtD
Pseudoephedrine—Nausea—Methotrexate—hematologic cancer	2.54e-05	0.000206	CcSEcCtD
Pseudoephedrine—Rash—Epirubicin—hematologic cancer	2.53e-05	0.000204	CcSEcCtD
Pseudoephedrine—Dermatitis—Epirubicin—hematologic cancer	2.52e-05	0.000204	CcSEcCtD
Pseudoephedrine—Headache—Epirubicin—hematologic cancer	2.51e-05	0.000203	CcSEcCtD
Pseudoephedrine—Dizziness—Doxorubicin—hematologic cancer	2.45e-05	0.000198	CcSEcCtD
Pseudoephedrine—Nausea—Epirubicin—hematologic cancer	2.38e-05	0.000193	CcSEcCtD
Pseudoephedrine—Vomiting—Doxorubicin—hematologic cancer	2.36e-05	0.000191	CcSEcCtD
Pseudoephedrine—Rash—Doxorubicin—hematologic cancer	2.34e-05	0.000189	CcSEcCtD
Pseudoephedrine—Dermatitis—Doxorubicin—hematologic cancer	2.34e-05	0.000189	CcSEcCtD
Pseudoephedrine—Headache—Doxorubicin—hematologic cancer	2.32e-05	0.000188	CcSEcCtD
Pseudoephedrine—Nausea—Doxorubicin—hematologic cancer	2.2e-05	0.000178	CcSEcCtD
Pseudoephedrine—ADRA2A—Signaling Pathways—PDGFRB—hematologic cancer	1.38e-06	8.42e-06	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—PTPN11—hematologic cancer	1.38e-06	8.4e-06	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—CD80—hematologic cancer	1.38e-06	8.38e-06	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—PIK3CG—hematologic cancer	1.37e-06	8.37e-06	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—KIT—hematologic cancer	1.37e-06	8.37e-06	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling by GPCR—NRAS—hematologic cancer	1.37e-06	8.37e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—PIK3CB—hematologic cancer	1.37e-06	8.34e-06	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—CYCS—hematologic cancer	1.37e-06	8.33e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—IL2RA—hematologic cancer	1.36e-06	8.31e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—PDGFRA—hematologic cancer	1.36e-06	8.29e-06	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—HSP90AA1—hematologic cancer	1.36e-06	8.28e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—JAK1—hematologic cancer	1.36e-06	8.26e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—PRKCG—hematologic cancer	1.36e-06	8.26e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling by GPCR—IL2—hematologic cancer	1.35e-06	8.24e-06	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—PTPN11—hematologic cancer	1.35e-06	8.22e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—TERT—hematologic cancer	1.35e-06	8.21e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Hemostasis—HRAS—hematologic cancer	1.35e-06	8.2e-06	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling by GPCR—MAPK3—hematologic cancer	1.35e-06	8.19e-06	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—CREB1—hematologic cancer	1.34e-06	8.14e-06	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—BRAF—hematologic cancer	1.32e-06	8.04e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—PDGFB—hematologic cancer	1.32e-06	8.02e-06	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling by GPCR—MAPK3—hematologic cancer	1.32e-06	8.01e-06	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—CCL2—hematologic cancer	1.31e-06	7.96e-06	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—CREB1—hematologic cancer	1.31e-06	7.96e-06	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—IL6R—hematologic cancer	1.3e-06	7.94e-06	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—CREBBP—hematologic cancer	1.3e-06	7.93e-06	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—BRAF—hematologic cancer	1.29e-06	7.86e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—TSC2—hematologic cancer	1.29e-06	7.83e-06	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—CCL2—hematologic cancer	1.28e-06	7.79e-06	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—IL6R—hematologic cancer	1.28e-06	7.77e-06	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—CREBBP—hematologic cancer	1.27e-06	7.76e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—IL2RA—hematologic cancer	1.27e-06	7.72e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—PIK3CG—hematologic cancer	1.26e-06	7.69e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—IL2—hematologic cancer	1.26e-06	7.66e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—TERT—hematologic cancer	1.25e-06	7.63e-06	CbGpPWpGaD
Pseudoephedrine—MAOA—Metabolism—PTEN—hematologic cancer	1.25e-06	7.62e-06	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—MAP2K1—hematologic cancer	1.24e-06	7.57e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—FGFR3—hematologic cancer	1.24e-06	7.54e-06	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—PIK3CD—hematologic cancer	1.23e-06	7.52e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—MAPK14—hematologic cancer	1.23e-06	7.46e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—PDGFB—hematologic cancer	1.22e-06	7.45e-06	CbGpPWpGaD
Pseudoephedrine—ADRB1—GPCR downstream signaling—PIK3CA—hematologic cancer	1.22e-06	7.45e-06	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—MAP2K1—hematologic cancer	1.22e-06	7.4e-06	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling by GPCR—KRAS—hematologic cancer	1.21e-06	7.36e-06	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—PIK3CD—hematologic cancer	1.21e-06	7.35e-06	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—GSTP1—hematologic cancer	1.21e-06	7.34e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—ESR1—hematologic cancer	1.2e-06	7.32e-06	CbGpPWpGaD
Pseudoephedrine—ADRB2—GPCR downstream signaling—PIK3CA—hematologic cancer	1.2e-06	7.28e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—TSC2—hematologic cancer	1.2e-06	7.28e-06	CbGpPWpGaD
Pseudoephedrine—MAOA—Metabolism—EP300—hematologic cancer	1.19e-06	7.27e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Hemostasis—AKT1—hematologic cancer	1.19e-06	7.24e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—FN1—hematologic cancer	1.19e-06	7.23e-06	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling by GPCR—KRAS—hematologic cancer	1.18e-06	7.2e-06	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—FGF2—hematologic cancer	1.18e-06	7.2e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—NFKBIA—hematologic cancer	1.17e-06	7.14e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—BAD—hematologic cancer	1.17e-06	7.14e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—CREBBP—hematologic cancer	1.17e-06	7.13e-06	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—PIK3R1—hematologic cancer	1.17e-06	7.1e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—NOTCH1—hematologic cancer	1.16e-06	7.08e-06	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—FGF2—hematologic cancer	1.16e-06	7.04e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—FGFR3—hematologic cancer	1.15e-06	7e-06	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—ABCB1—hematologic cancer	1.14e-06	6.95e-06	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—PIK3R1—hematologic cancer	1.14e-06	6.94e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—MAPK14—hematologic cancer	1.14e-06	6.93e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—CD80—hematologic cancer	1.14e-06	6.93e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—PIK3CG—hematologic cancer	1.14e-06	6.92e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—KIT—hematologic cancer	1.14e-06	6.92e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling by GPCR—NRAS—hematologic cancer	1.14e-06	6.92e-06	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—JAK2—hematologic cancer	1.13e-06	6.9e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—ESR1—hematologic cancer	1.12e-06	6.8e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—PTPN11—hematologic cancer	1.12e-06	6.8e-06	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling by GPCR—PIK3CA—hematologic cancer	1.11e-06	6.76e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—PIK3CD—hematologic cancer	1.11e-06	6.76e-06	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—JAK2—hematologic cancer	1.11e-06	6.75e-06	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—NCOR1—hematologic cancer	1.11e-06	6.75e-06	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—GSTM1—hematologic cancer	1.11e-06	6.75e-06	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—MDM2—hematologic cancer	1.11e-06	6.74e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—FN1—hematologic cancer	1.1e-06	6.72e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—ALB—hematologic cancer	1.1e-06	6.67e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—NFKBIA—hematologic cancer	1.09e-06	6.64e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—BAD—hematologic cancer	1.09e-06	6.64e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling by GPCR—MAPK3—hematologic cancer	1.09e-06	6.63e-06	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling by GPCR—PIK3CA—hematologic cancer	1.09e-06	6.61e-06	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—MDM2—hematologic cancer	1.08e-06	6.59e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—CREB1—hematologic cancer	1.08e-06	6.59e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—NOTCH1—hematologic cancer	1.08e-06	6.57e-06	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—PIK3CB—hematologic cancer	1.08e-06	6.55e-06	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—MTOR—hematologic cancer	1.08e-06	6.55e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—BRAF—hematologic cancer	1.07e-06	6.5e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—CCL2—hematologic cancer	1.06e-06	6.44e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—CD80—hematologic cancer	1.06e-06	6.44e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—KIT—hematologic cancer	1.06e-06	6.43e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—PIK3CG—hematologic cancer	1.06e-06	6.43e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—NRAS—hematologic cancer	1.06e-06	6.43e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—IL6R—hematologic cancer	1.06e-06	6.43e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—CREBBP—hematologic cancer	1.05e-06	6.42e-06	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—MTOR—hematologic cancer	1.05e-06	6.41e-06	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—PIK3CB—hematologic cancer	1.05e-06	6.41e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—PIK3R1—hematologic cancer	1.05e-06	6.38e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—PTPN11—hematologic cancer	1.04e-06	6.32e-06	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling by GPCR—HRAS—hematologic cancer	1.03e-06	6.26e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—MAPK3—hematologic cancer	1.01e-06	6.16e-06	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—CDKN1B—hematologic cancer	1.01e-06	6.15e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—MAP2K1—hematologic cancer	1.01e-06	6.12e-06	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling by GPCR—HRAS—hematologic cancer	1.01e-06	6.12e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—CREB1—hematologic cancer	1.01e-06	6.12e-06	CbGpPWpGaD
Pseudoephedrine—ADRB1—GPCR downstream signaling—AKT1—hematologic cancer	9.99e-07	6.08e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—PIK3CD—hematologic cancer	9.99e-07	6.08e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—BRAF—hematologic cancer	9.93e-07	6.04e-06	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—CASP3—hematologic cancer	9.9e-07	6.03e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—GPCR downstream signaling—PIK3CA—hematologic cancer	9.9e-07	6.03e-06	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—IL2—hematologic cancer	9.88e-07	6.02e-06	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—CDKN1B—hematologic cancer	9.88e-07	6.02e-06	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling by GPCR—IL6—hematologic cancer	9.83e-07	5.99e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—CCL2—hematologic cancer	9.83e-07	5.99e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—IL6R—hematologic cancer	9.81e-07	5.97e-06	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—MTHFR—hematologic cancer	9.79e-07	5.96e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—CREBBP—hematologic cancer	9.79e-07	5.96e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling by GPCR—KRAS—hematologic cancer	9.78e-07	5.96e-06	CbGpPWpGaD
Pseudoephedrine—ADRB2—GPCR downstream signaling—AKT1—hematologic cancer	9.77e-07	5.95e-06	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—CASP3—hematologic cancer	9.68e-07	5.9e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—PIK3CB—hematologic cancer	9.68e-07	5.89e-06	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—IL2—hematologic cancer	9.67e-07	5.89e-06	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—CCND1—hematologic cancer	9.64e-07	5.87e-06	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling by GPCR—IL6—hematologic cancer	9.62e-07	5.86e-06	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—JUN—hematologic cancer	9.62e-07	5.85e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—FGF2—hematologic cancer	9.57e-07	5.82e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—PIK3R1—hematologic cancer	9.43e-07	5.74e-06	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—CCND1—hematologic cancer	9.43e-07	5.74e-06	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—JUN—hematologic cancer	9.41e-07	5.73e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—MAP2K1—hematologic cancer	9.34e-07	5.69e-06	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—CDKN1A—hematologic cancer	9.32e-07	5.68e-06	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—PTEN—hematologic cancer	9.3e-07	5.66e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—PIK3CD—hematologic cancer	9.28e-07	5.65e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—GPCR downstream signaling—PIK3CA—hematologic cancer	9.19e-07	5.6e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—JAK2—hematologic cancer	9.17e-07	5.58e-06	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—CDKN1A—hematologic cancer	9.12e-07	5.55e-06	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—MAPK8—hematologic cancer	9.1e-07	5.54e-06	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—PTEN—hematologic cancer	9.1e-07	5.54e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—KRAS—hematologic cancer	9.09e-07	5.53e-06	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling by GPCR—AKT1—hematologic cancer	9.07e-07	5.52e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling by GPCR—PIK3CA—hematologic cancer	8.99e-07	5.47e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—MDM2—hematologic cancer	8.95e-07	5.45e-06	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—MAPK8—hematologic cancer	8.9e-07	5.42e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—FGF2—hematologic cancer	8.89e-07	5.41e-06	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling by GPCR—AKT1—hematologic cancer	8.88e-07	5.4e-06	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—EP300—hematologic cancer	8.87e-07	5.4e-06	CbGpPWpGaD
Pseudoephedrine—MAOA—Metabolism—PIK3CA—hematologic cancer	8.83e-07	5.38e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—PIK3R1—hematologic cancer	8.77e-07	5.34e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—PIK3CB—hematologic cancer	8.71e-07	5.3e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—MTOR—hematologic cancer	8.71e-07	5.3e-06	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—EP300—hematologic cancer	8.68e-07	5.28e-06	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—SRC—hematologic cancer	8.62e-07	5.25e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—JAK2—hematologic cancer	8.52e-07	5.19e-06	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—SRC—hematologic cancer	8.44e-07	5.14e-06	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—VEGFA—hematologic cancer	8.4e-07	5.11e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—PTEN—hematologic cancer	8.36e-07	5.09e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—PIK3CA—hematologic cancer	8.35e-07	5.08e-06	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—STAT3—hematologic cancer	8.32e-07	5.06e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—MDM2—hematologic cancer	8.32e-07	5.06e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling by GPCR—HRAS—hematologic cancer	8.31e-07	5.06e-06	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—NRAS—hematologic cancer	8.3e-07	5.05e-06	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—PIK3CG—hematologic cancer	8.23e-07	5.01e-06	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—VEGFA—hematologic cancer	8.22e-07	5e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—CDKN1B—hematologic cancer	8.17e-07	4.98e-06	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—STAT3—hematologic cancer	8.14e-07	4.95e-06	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—NRAS—hematologic cancer	8.12e-07	4.94e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—PIK3CB—hematologic cancer	8.09e-07	4.93e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—MTOR—hematologic cancer	8.09e-07	4.93e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—GPCR downstream signaling—AKT1—hematologic cancer	8.08e-07	4.92e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—CASP3—hematologic cancer	8.01e-07	4.88e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—IL2—hematologic cancer	8e-07	4.87e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—EP300—hematologic cancer	7.97e-07	4.86e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling by GPCR—IL6—hematologic cancer	7.96e-07	4.84e-06	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—MAPK3—hematologic cancer	7.95e-07	4.84e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—CCND1—hematologic cancer	7.8e-07	4.75e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—JUN—hematologic cancer	7.78e-07	4.74e-06	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—MAPK3—hematologic cancer	7.77e-07	4.73e-06	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—MYC—hematologic cancer	7.73e-07	4.71e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—HRAS—hematologic cancer	7.73e-07	4.7e-06	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—TGFB1—hematologic cancer	7.71e-07	4.69e-06	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—CREBBP—hematologic cancer	7.63e-07	4.65e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—CDKN1B—hematologic cancer	7.59e-07	4.62e-06	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—MYC—hematologic cancer	7.56e-07	4.6e-06	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—TGFB1—hematologic cancer	7.54e-07	4.59e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—CDKN1A—hematologic cancer	7.54e-07	4.59e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—PTEN—hematologic cancer	7.53e-07	4.58e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—GPCR downstream signaling—AKT1—hematologic cancer	7.51e-07	4.57e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—CASP3—hematologic cancer	7.44e-07	4.53e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—IL2—hematologic cancer	7.43e-07	4.52e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—IL6—hematologic cancer	7.39e-07	4.5e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—MAPK8—hematologic cancer	7.36e-07	4.48e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling by GPCR—AKT1—hematologic cancer	7.34e-07	4.47e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—CCND1—hematologic cancer	7.24e-07	4.41e-06	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—PIK3CD—hematologic cancer	7.23e-07	4.4e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—JUN—hematologic cancer	7.23e-07	4.4e-06	CbGpPWpGaD
Pseudoephedrine—MAOA—Metabolism—AKT1—hematologic cancer	7.21e-07	4.39e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—EP300—hematologic cancer	7.18e-07	4.37e-06	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—KRAS—hematologic cancer	7.14e-07	4.35e-06	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—ALB—hematologic cancer	7.14e-07	4.35e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—CDKN1A—hematologic cancer	7.01e-07	4.27e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—PTEN—hematologic cancer	6.99e-07	4.26e-06	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—KRAS—hematologic cancer	6.99e-07	4.25e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—SRC—hematologic cancer	6.98e-07	4.25e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—MAPK8—hematologic cancer	6.84e-07	4.16e-06	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—PIK3R1—hematologic cancer	6.83e-07	4.16e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—AKT1—hematologic cancer	6.82e-07	4.15e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—VEGFA—hematologic cancer	6.8e-07	4.14e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—STAT3—hematologic cancer	6.73e-07	4.1e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—NRAS—hematologic cancer	6.71e-07	4.09e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—EP300—hematologic cancer	6.67e-07	4.06e-06	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—PIK3CA—hematologic cancer	6.56e-07	3.99e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—SRC—hematologic cancer	6.48e-07	3.95e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—MAPK3—hematologic cancer	6.43e-07	3.91e-06	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—PIK3CA—hematologic cancer	6.42e-07	3.91e-06	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—TP53—hematologic cancer	6.35e-07	3.86e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—VEGFA—hematologic cancer	6.32e-07	3.84e-06	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—PIK3CB—hematologic cancer	6.31e-07	3.84e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—MYC—hematologic cancer	6.25e-07	3.81e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—STAT3—hematologic cancer	6.25e-07	3.81e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—TGFB1—hematologic cancer	6.24e-07	3.8e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—NRAS—hematologic cancer	6.24e-07	3.8e-06	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—TP53—hematologic cancer	6.21e-07	3.78e-06	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—HRAS—hematologic cancer	6.07e-07	3.7e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—MAPK3—hematologic cancer	5.97e-07	3.64e-06	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—HRAS—hematologic cancer	5.94e-07	3.62e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—PIK3CA—hematologic cancer	5.9e-07	3.59e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—MYC—hematologic cancer	5.81e-07	3.54e-06	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—IL6—hematologic cancer	5.81e-07	3.54e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—TGFB1—hematologic cancer	5.8e-07	3.53e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—KRAS—hematologic cancer	5.78e-07	3.52e-06	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—IL6—hematologic cancer	5.68e-07	3.46e-06	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—PTEN—hematologic cancer	5.45e-07	3.32e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—KRAS—hematologic cancer	5.37e-07	3.27e-06	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—AKT1—hematologic cancer	5.36e-07	3.26e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—PIK3CA—hematologic cancer	5.31e-07	3.23e-06	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—AKT1—hematologic cancer	5.24e-07	3.19e-06	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—EP300—hematologic cancer	5.2e-07	3.16e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—TP53—hematologic cancer	5.14e-07	3.13e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—PIK3CA—hematologic cancer	4.93e-07	3e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—HRAS—hematologic cancer	4.91e-07	2.99e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—AKT1—hematologic cancer	4.82e-07	2.93e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—TP53—hematologic cancer	4.77e-07	2.91e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—IL6—hematologic cancer	4.7e-07	2.86e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—HRAS—hematologic cancer	4.56e-07	2.78e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—IL6—hematologic cancer	4.37e-07	2.66e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—AKT1—hematologic cancer	4.34e-07	2.64e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—AKT1—hematologic cancer	4.03e-07	2.45e-06	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—PIK3CA—hematologic cancer	3.84e-07	2.34e-06	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—AKT1—hematologic cancer	3.14e-07	1.91e-06	CbGpPWpGaD
